ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

DCCR Advisors Okay New Programs; $300,000 Year Demonstrations In Six Communities Supported

November 17, 1978

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

Coalitions Diverge On NIH Role, Agree On Need For More Basic Research

February 19, 1993

Book For Survivors, Other New Publications

August 23, 1991

NCI Low Fat Diet Study For Stage 2 Breast Cancer Will Include Postmenopausal Tamxifen Therapy

September 20, 1985

NIH Funding Opportunities Listed

March 13, 2009